NCT06508216: A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 50 planned
- Started
- 5 Jul 2024
- Primary completion
- 17 Dec 2025
- Arms
- Module 2 of part 2 : Datopotamab Deruxtecan (Dato-DXd) + Durvalumab
- Results
- None posted
- 5 Jul 2024: Trial started
- 18 Jul 2024: Trial registered